Salix to Acquire Oceana Therapeutics; Anacor Completes Enrollment in First of Two Phase 3 Trials of AN2690 Print E-mail
By Staff and Wire Reports   
Wednesday, 09 November 2011 19:31
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 9, 2011.

Salix Pharmaceuticals (Nasdaq:SLXP ) rose 6.0 percent after announcing that Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash. The transaction is subject to customary conditions to closing, including U.S. anti-trust approval, and is expected to close in December 2011.

“The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix’s base business and provides immediate added revenue,” stated Carolyn Logan, President and Chief Executive Officer, Salix. “Oceana markets two differentiated products - SOLESTA®; a first-in-class, biocompatible tissue bulking agent for the treatment of fecal incontinence; and DEFLUX®, the only FDA-approved alternative to major ureteral reimplantation surgery for the treatment of vesicoureteral reflux.


Anacor Pharmaceuticals (NASDAQ: ANAC) announced it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

Also Wednesday:

Abiomed Inc. (NASDAQ: ABMD)
, a leading provider of breakthrough heart support technologies, today announced the final analysis from the PROTECT II trial at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) meeting.

Advanced Cell Technology, Inc. (“ACT”, OTCBB: ACTC)
, a leader in the field of regenerative medicine, today announced third quarter financial results for the period ended September 30, 2011.

Affymax, Inc. (Nasdaq:AFFY)
today announced that it has reached a global settlement agreement with Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) and certain of its affiliated companies to end the arbitration and litigation related to certain intellectual property emerging from a 1992-1995 research collaboration.

Alkermes plc (NASDAQ: ALKS)
today presented positive results from a long-term study of VIVITROL® (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

AMERICAN SHARED HOSPITAL SERVICES (NYSE AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that the Gamma Knife® Perfexion™ system it supplied to St. Vincent's Medical Center in Jacksonville, Florida has begun treating patients.

AMRI (NASDAQ: AMRI), a global contract services organization with services spanning the entire R&D continuum, announced today that it has entered into an agreement with Revolymer®, a technology development company located in the United Kingdom, to become its primary manufacturer and supplier of Rev7™, AGC and other polymers, main components of the company’s revolutionary Rev7™ degradable gum products.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Lazard Capital Markets Healthcare Conference in New York City.

Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2011. The net loss for the third quarter of 2011 was $9.8 million compared to a net loss of $12.0 million for the third quarter of 2010.

Bio-Reference Laboratories, Inc (NASDAQ-BRLI) announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011, at The Pierre Hotel located in New York, NY.

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Lazard Capital Markets 8th Annual Healthcare Conference at 8:30am EST on Wednesday, November 16, 2011 in New York, NY.

Biotech developer Divine Skin Inc. (OTC Bulletin Board: DSKX) which has been expanding the topical hair-growth segment, is rolling out that market's newest, most potent, only customizable system, Polaris API Solution 9, to be supplied by physicians for treatment through multiple methods of action.

Dako announced today it has entered into a broad framework agreement with Bristol-Myers Squibb Company (NYSE: BMY) on the development of pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb.

Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the preparation to release of the second Cannabis Science brand formulation.

Cerus Corporation (NASDAQ:CERS) announced today that Dr. Laurence Corash, chief medical officer, is scheduled to present a corporate update at the Stephens Inc. Fall Conference in New York at 2:00 PM EDT on Wednesday, November 16, 2011.

Corning Incorporated (NYSE: GLW) today announced the official opening of a new state-of-the-art manufacturing and distribution facility for Corning Life Sciences in China’s Yangtze River Delta.

Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Lazard Capital Markets Healthcare Conference in New York on November 16, 2011.

Enzo Biochem, Inc. (NYSE:ENZ), a leading vertically integrated clinical lab, life sciences and therapeutic biotechnology company, announced today that Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, will be presenting at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011 at 11:30 AM at The Pierre Hotel in New York, N.Y.

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that its Xoft Axxent® eBx™ electronic brachytherapy system for intraoperative radiation therapy (IORT) has been recently adopted at leading hospitals across the country.

Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following three investor conferences in November.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from clinical trials of Zerenex™ (ferric citrate) have been accepted for poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2011 Annual Meeting and exposition taking place November 8-13 in Philadelphia.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center will be presenting data from Lexicon's LX2931 Phase 2 proof-of-concept clinical trial at the annual meeting of the American College of Rheumatology on Wednesday, November 9, 2011 in Chicago, Illinois.  

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided a clinical update on the Company’s progress with the development of its Biopump which is being developed for the treatment of a range of chronic diseases including anemia and hepatitis C.

Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal Disorders and Techniquesthat demonstrates the effectiveness of the Aquamantys® System in limiting blood loss and reducing transfusions during spinal corrective surgery.

Merck (NYSE: MRK) today announced that NEXPLANON®(etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

NewCardio, Inc., (OTCBB: NWCI) a cardiovascular diagnostic solutions developer, announced today that its strategic partner, Clinilabs, will utilize QTinno®, NewCardio's automated cardiac safety solution, to conduct a Phase I trial of an investigational new drug under development for a central nervous system (CNS) indication.  

Nuvilex, Inc. (OTCQB:NVLX)
through SG Austria, an international provider of live cell encapsulation and services to the biotechnology and pharmaceutical industries, is highlighting the unique aspects of its technology with live stem cells.

ProPhase Labs (NASDAQ: PRPH) today reported net sales of $5.1 million for the three months ended September 30, 2011, compared to net sales of $5.2 million for the three months ended September 30, 2010.

Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGETM) Labs, an initiative of Sigma Life Science, in partnership with Autism Speaks, will present data on the biological and behavioral characterization of the first rats genetically engineered to model autism.

Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the positive top-line results from its phase II clinical trial for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which causes hand, foot and mouth disease (HFMD).

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that an overview of the Company’s business strategy will be given at the Lazard Capital Markets 8th Annual Healthcare Conference, being held at The Pierre Hotel in New York City.

Synageva BioPharma Corp. (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders announced today that it will be presenting at the upcoming Lazard Capital Markets 8th Annual Healthcare Conference, which is being held Nov. 15-16, at The Pierre Hotel in New York City.

Transgenomic, Inc.(OTCBB: TBIO) today announced the following Webcast:  What:  Transgenomic, Inc. Third Quarter 2011 Financial Results and Business Update Conference Call.  When:     Wednesday, November 9, 2011 @ 5:00 p.m. Eastern.

Unigene Laboratories, Inc.(OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced positive top-line results of its Phase 2 clinical study evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in 93 postmenopausal women.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus